Calendario›LTGO›LTG-001 High Dose

LTG-001 High Dose

This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars

Ensayo de Latigo Biotherapeutics, Inc. en Acute Pain, Postoperative (del registro, en inglés).

Fase

Fase 2

Estado

Completado

Participantes

250

previstos

Centros

1

Fin del objetivo primario

ago 2025

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en dic 2024.

Qué mide

SPID 0-12 (del registro, en inglés) (12 horas)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe goal of this clinical trial is to learn if LTG-001 works to treat pain after third molar removal surgery in adults. It will also learn about the safety of LTG-001. The main questions it aims to answer are: Does drug LTG-001 treat the acute pain after surgical removal of impacted third molars (wisdom teeth) over 12 hours? How tolerable is LTG-001 after surgical removal of impacted third molars (wisdom teeth) over 12 hours? Researchers in Part 1 will compare drug LTG-001 to a placebo (a look-alike substance that contains no drug) and in Part 2 to a placebo and a comparator to see if drug LTG-001 treats the post-surgical pain. Participants will: Take LTG-001 one time after the surgical removal of impacted third molars. Remain at the clinic for 12 hours after study dosing and return after a week for a safety check up. Report the pain relief during the 12 hours after dosing to record changes in the post-operative pain

Más ensayos de LTGO

Todos los de LTGO, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06774625), actualizada en may 2026.